The group of eight centers will be financed for two years.
Aptium Oncology has initiated the Aptium Oncology Gastrointestinal Cancer Consortium (AGICC), consisting of eight member institutions. These institutions are funded for two years via a support grant to be used in expanding and supplementing their ongoing clinical/translational gastrointestinal (GI) cancer programs.
The consortium includes five university cancer center programs and three large private groups. They include the University of Southern California, Vanderbilt-Ingram Cancer Center, University of Colorado Cancer Center, University of North Carolina Lineberger Comprehensive Cancer Center, NYU Langone Medical Center, Fox Chase Cancer Center Partners, Swedish Cancer Institute, and Christiana Care’s Helen F. Graham Cancer Center.
The goal of the GI Consortium is to find and efficiently test new compounds for patients with GI cancers. Enrollment of the first patients in clinical trials is expected for January of 2009.
